DICE Therapeutics
Suzette Mangan has extensive experience in HR and talent development roles. Suzette is currently employed as a Sr. HR Generalist at DICE Therapeutics since 2022. Prior to that, they worked as a Senior Talent Coordinator at Puma Biotechnology, Inc. from 2018. Suzette also gained experience at Merck & Co., Inc. as an HR Coordinator from 2017 to 2018. Before joining Merck, they served as the Manager of Professional Development at QuinStreet, Inc. from 2006 to 2016. Earlier in their career, Suzette held roles such as Employee Development Training Coordinator at First DataBank, Inc. from 2000 to 2006 and was involved in Training & Development at Consolidated Freightways from 1991 to 2000.
Suzette Mangan's education history includes studying at California State University - East Bay. However, the duration of their studies, the degree obtained, and the field of study are not specified.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.